[1] 刘瑞双, 徐原宁, 陈茂. 重度主动脉瓣狭窄行TAVR治疗方案临床效果的循证病案讨论[J]. 中国循证医学杂志, 2017, 17(2): 243.
[2] 高健萱, 张恒. 经导管主动脉瓣置入术治疗老年退行性心脏瓣膜病研究进展[J]. 蚌埠医学院学报, 2019, 44(2): 279.
[3] MAEDER MT, WEBER L, BUSER M, et al. Pulmonary hypertension in aortic and mitral valve disease[J]. Front Cardiovasc Med, 2018, 23, 5: 40.
[4] SINNING JW, WOLLERT KC, SEDAGHAT A, et al. Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement[J]. Am Heart J, 2015, 170(4): 821. doi: 10.1016/j.ahj.2015.07.003
[5] REDFORS B, FURER A, LINDMAN BR, et al. Biomarkers in aortic stenosis: a systematic review[J]. Structural Heart, 2017, 1: 18. doi: 10.1080/24748706.2017.1329959
[6] 任永凤, 王洲, 李健, 等. 2D-STI评价亚临床型重度主动脉瓣狭窄病人左心室功能及相关性研究[J]. 蚌埠医学院学报, 2019, 44(3): 366.
[7] 王新房, 谢明星. 超声心动图学[M]. 5版. 北京: 人民卫生出版社, 2017: 711.
[8] ALUSHI B, BECKHOFF F, LEISTNER D, et al. Pulmonary hypertension in patients with severe aortic stenosis: prognostic impact after transcatheter aortic valve replacement: Pulmonary hypertension in patients undergoing TAVR[J]. JACC Cardiovasc Imaging, 2019, 12(4): 591. doi: 10.1016/j.jcmg.2018.02.015
[9] AHN HS, CHANG SA, KIM HK, et al. Determinants of pulmonary hypertension development in moderate or severe aortic stenosis[J]. Int J Cardiovasc Imaging, 2014, 30(8): 1519. doi: 10.1007/s10554-014-0498-5
[10] 代雪, 王珂. 左心疾病相关性肺高压的病因研究和临床特征分析[J]. 中国心血管病研, 2018, 2(16): 163.
[11] 谭羽莹, 王小丛, 徐晶, 等. 三维斑点追踪成像结合二维超声评价不同程度肺动脉高压病人左心功能[J]. 中国医学影像学杂志, 2017, 25(9): 678. doi: 10.3969/j.issn.1005-5185.2017.09.012
[12] 任永凤, 郑慧, 王洲. 二维斑点追踪技术评价维持性血液透析病人左心室整体收缩功能及肺动脉高压影响因素研究[J]. 中国全科医学, 2016, 19(3): 359. doi: 10.3969/j.issn.1007-9572.2016.03.026
[13] 刘文旭, 赵映, 何怡华, 等. 二维斑点追踪技术评价不同程度主动脉瓣狭窄患者左心室收缩功能[J]. 心肺血管病杂志, 2014, 33(3): 410. doi: 10.3969/j.issn.1007-5062.2014.03.026
[14] RAINA A, GERTZ ZM, O'DONNELL WT, et al. Pulmonary hypertension is a manifestation of congestive heart failure and left ventricular diastolic dysfunction in octogenarians with severe aortic stenosis[J]. Pulm Circ, 2015, 5(3): 521. doi: 10.1086/682226
[15] CASACLANG-VERZOSA G, NKOMO VT, SARANO ME, et al. E/Ea is the major determinant of pulmonary artery pressure in moderate to severe aortic stenosis[J]. J Am Soc Echocardiogr, 2008, 21(7): 824. doi: 10.1016/j.echo.2007.12.002
[16] KAPOOR N, VARADARAJAN P, PAI RG.Echocardiographic predictors of pulmonary hypertension in patients with severe aortic stenosis[J]. Eur J Echocardiogr, 2008, 9(1): 31.
[17] 李文霞, 陈漠水, 张光星, 等. GDF-15在扩张型心肌病患者中的变化及其与NT-proBNP的关系[J]. 中国循证心血管医学杂志, 2017, 9(9): 1055. doi: 10.3969/j.issn.1674-4055.2017.09.09
[18] GAGGIN HK, SYMONIFKA J, BHARDWAJ A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly- sensitive troponin T measurements in patients with chronic heart failure[J]. JACC Heart Fail, 2014, 2(1): 65. doi: 10.1016/j.jchf.2013.10.005
[19] CASSERLY B, KLINGER JR.Brain natriuretic peptide in pulmonary arterial hypertension: Biomarker and potential therapeutic agent[J]. Drug Des Devel Ther, 2009, 29(3): 269.
[20] BAUMGARTNER H, FALK V, BAX JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease[J]. Rev Esp cardiol(Engl Ed), 2018, 71(2): 110.
[21] WOLLERT KC, KEMPF T.Growth differentiation factor 15 in heart failure: an update[J]. Curr Heart Fail Rep, 2012, 9(4): 337. doi: 10.1007/s11897-012-0113-9
[22] HERINGLAKE M, CHARITOS EI, GATZ N, et al. Growth differentiation factor 15: a novel risk marker adjunct to the Euroscore for risk stratification in cardiac surgery patients[J]. J Am Coll Cardiol, 2013, 61(6): 672. doi: 10.1016/j.jacc.2012.09.059
[23] IKEDA Y, KUMAGAI H, MOTOZAWA Y, et al. Growth differentiation factor 15(GDF-15)as a reliable biomarker for cardiovascular risk assessment[J]. Int Heart J, 2016, 57(1): 1. doi: 10.1536/ihj.15-324
[24] KRAU NC, LUNSTEDT NS, FREITAG-WOLF S, et al. Elevated growth differentiation factor 15 levels predict outcome in patients undergoing transcatheter aortic valve implantation[J]. Eur J Heart Fail, 2015, 17(9): 945. doi: 10.1002/ejhf.318